IL2 and metastatic melanoma: Also renal cell carcinomas are as sensitive to systemic administration of IL-2 as metastatic melanoma yet, while in the latter adaptive immune responses are easily demonstrable, in the former, they have been quite elusive, and most likely of secondary significance [38,39].